Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET
May 18 2021 - 7:30AM
Business Wire
Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX)
("Brooklyn" or the “Company”), a biopharmaceutical company
currently focused on exploring the role that cytokine and gene
editing/cell therapy can have in treating patients with cancer,
blood disorders and monogenic diseases, today announced that
management will host a conference call on Tuesday, May 25, 2021 at
4:30 p.m. Eastern Time (ET).
Participants are asked to pre-register for the call through the
following link:
http://www.directeventreg.com/registration/event/6819283. Please
note that registered participants will receive their dial in number
upon registration and will dial directly into the call.
The conference call will also be available through a live
webcast found here.
The Company invites participants to pre-submit questions to
investors@brooklyntx.com until 5:00 p.m. Eastern Time (ET) on May
20, 2021 (live questions will not be accepted during the call).
Please use the subject line, “BTX Call Questions” for this
correspondence. The Company will do its best to address all
pre-submitted questions at the conclusion of prepared remarks.
About Brooklyn ImmunoTherapeutics
Brooklyn is focused on exploring the role that cytokine-based
therapy can have in treating patients with cancer, both as a single
agent and in combination with other anti-cancer therapies. The
company is also expoloring opportunities to advance oncology, blood
disorders, and monogenic disease therapies using leading edge gene
editing/cell therapy technology through the newly acquired license
from Factor Bioscience Limited and Novellus Therapeutics
Limited.
Brooklyn’s most advanced program is studying the safety and
efficacy of IRX-2 in patients with head and neck cancer. In a Phase
2A clinical trial in head and neck cancer, IRX-2 demonstrated an
overall survival benefit. Additional studies are either underway or
planned in other solid tumor cancer indications.
For more information about Brooklyn and its clinical programs,
please visit www.BrooklynITx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210518005370/en/
Investor Relations Contact: CORE IR 516-222-2560
investors@brooklynitx.com
Media Contact: MacDougall Nicholas Chang
nchang@macbiocom.com 781-235-3060
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Jul 2023 to Jul 2024